Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Unresectable or Metastatic NSCLC Harboring RAS Mutations

    Cancer Categories
    • Lung
    Karmanos Trial ID
    • 2025-028
    NCT ID
    • NCT06881784
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator
    • Tarik
      Hadid, M.D., MPH, MS, FACP

      Oncology - Medical View Profile

    Objective:

    Primary:

    In the RAS (G12X-C) population, i.e., RAS G12X excluding G12C:

    • To compare the treatment effect of RMC-6236 versus docetaxel on:
      • PFS (per Investigator)
      • OS

    Key Secondary

    In the RAS (MUT) population:

    • To compare the treatment effect of RMC-6236 versus docetaxel on:
      • PFS (per Investigator)
      • OS

    In the RAS (G12X-C) and RAS (MUT) populations:

    • To compare the treatment effect of RMC-6236 versus docetaxel on objective response (per Investigator)

    Other Secondary

    In the RAS (G12X-C) and RAS (MUT) populations:

    • To compare the treatment effect of RMC-6236 versus docetaxel on:
      • PFS (per BICR)
      • Objective response (per BICR)

    In the RAS (G12X-C) and RAS (MUT) populations:

    • To compare the treatment effect of RMC-6236 versus docetaxel on:
      • DOR (per Investigator and per BICR)
      • TTR (per Investigator and per BICR)

    In the RAS (G12X-C) and RAS (MUT) populations:

    • To compare the treatment effect of RMC-6236 versus docetaxel on QoLs using EORTC QLQ-LC13 and EORTC QLQ-C30

    In the RAS (G12X-C) and RAS (MUT) population:

    • To compare safety and tolerability of RMC-6236 versus docetaxel

    In the RAS (MUT) population:

    • To characterize the PK of RMC-6236
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions